Recommended by expert medical guidelines
MammaPrint is included in numerous clinical practice guidelines developed by world-recognized cancer
care organizations. Clinical guidelines are evidence-based recommendations for healthcare
professionals involved in the management of patients.
Guidelines aim to improve the quality of care and services based on the most up to date
peer-reviewed evidence. For example, MammaPrint is the only test of its kind endorsed by the
American Society of Clinical Oncology for lymph node-positive patients.
Also included in the National Comprehensive Cancer Network® (NCCN®)
70-Gene Assay (MammaPrint) has a Category 1 recommendation from the National Comprehensive Cancer
Network® (NCCN®). Category 1 is based upon high-level evidence; there is uniform NCCN consensus that
intervention is appropriate. Referenced with permission from the NCCN Clinical Practice Guidelines
in Oncology (NCCN Guidelines®) for Breast Cancer V.1.2019. © 2019 National Comprehensive Cancer
Network, Inc 2019. All rights reserved. To view the most recent and complete version of the
guidelines, go to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content,
use or application and disclaims any responsibility for their application or use in any way.
70-gene Assay (MammaPrint) is the only genomic assay with FDA clearance and Level 1 evidence by the
American Society of Clinical Oncology (ASCO).